Optimal symptom combinations to aid COVID-19 case identification: Analysis from a community-based, prospective, observational cohort.
Optimal symptom combinations to aid COVID-19 case identification: Analysis from a community-based, prospective, observational cohort.
复制标题
DOI：
10.1016/j.jinf.2021.02.015
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Loeliger AE
中科院分区：
文献类型：
--
作者：
Antonelli M;Capdevila J;Chaudhari A;Granerod J;Canas LS;Graham MS;Klaser K;Modat M;Molteni E;Murray B;Sudre CH;Davies R;May A;Nguyen LH;Drew DA;Joshi A;Chan AT;Cramer JP;Spector T;Wolf J;Ourselin S;Steves CJ;Loeliger AE
对任何新冠肺炎相关症状进行的诊断工作将导致广泛的检测，可能会超出实验室能力，同时主要产生阴性结果。我们的目标是确定最佳的症状组合，以使用更少的测试来捕获大多数病例，这对不同资源设置和公共卫生的新冠肺炎疫苗开发人员具有影响。新冠肺炎症状研究应用的英国和美国用户报告了新的症状，并在症状出现后7天内进行了RT-PCR测试。对于不同的症状组合，计算了识别一个病例所需的灵敏度、特异度和RT-PCR试验次数(每例试验[TPC])。多目标进化算法被用来产生在敏感性和特异性之间具有最佳折衷的组合。英国和美国的队列包括122,305名(1,202名阳性)和3,162名(79名阳性)个人。在症状出现的三天内，新冠肺炎特有的症状组合(咳嗽、呼吸困难、发热、嗅觉障碍/嗅觉障碍)确定了需要47个TPC的69%的病例。敏感性最高的组合(乏力、嗅觉障碍/嗅觉障碍、咳嗽、腹泻、头痛、喉咙痛)确定了96%的病例需要96个TPC。我们确认了新冠肺炎特定症状对于触发RT-PCR的重要性，并确定了其他症状组合，这些组合具有敏感度和特异度之间的最佳折衷，可以在不同的资源设置下最大限度地捕获病例。
Diagnostic work-up following any COVID-19 associated symptom will lead to extensive testing, potentially overwhelming laboratory capacity whilst primarily yielding negative results. We aimed to identify optimal symptom combinations to capture most cases using fewer tests with implications for COVID-19 vaccine developers across different resource settings and public health. UK and US users of the COVID-19 Symptom Study app who reported new-onset symptoms and an RT-PCR test within seven days of symptom onset were included. Sensitivity, specificity, and number of RT-PCR tests needed to identify one case (test per case [TPC]) were calculated for different symptom combinations. A multi-objective evolutionary algorithm was applied to generate combinations with optimal trade-offs between sensitivity and specificity. UK and US cohorts included 122,305 (1,202 positives) and 3,162 (79 positive) individuals. Within three days of symptom onset, the COVID-19 specific symptom combination (cough, dyspnoea, fever, anosmia/ageusia) identified 69% of cases requiring 47 TPC. The combination with highest sensitivity (fatigue, anosmia/ageusia, cough, diarrhoea, headache, sore throat) identified 96% cases requiring 96 TPC. We confirmed the significance of COVID-19 specific symptoms for triggering RT-PCR and identified additional symptom combinations with optimal trade-offs between sensitivity and specificity that maximize case capture given different resource settings.
登录
查看更多内容
DOI：
10.1016/s0140-6736(20)32661-1
发表时间：
2021-01-09
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Clemens SAC;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Collins AM;Colin-Jones R;Cutland CL;Darton TC;Dheda K;Duncan CJA;Emary KRW;Ewer KJ;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Goodman AL;Green CM;Green CA;Heath PT;Hill C;Hill H;Hirsch I;Hodgson SHC;Izu A;Jackson S;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Lawrie AM;Lelliott A;Libri V;Lillie PJ;Mallory R;Mendes AVA;Milan EP;Minassian AM;McGregor A;Morrison H;Mujadidi YF;Nana A;O'Reilly PJ;Padayachee SD;Pittella A;Plested E;Pollock KM;Ramasamy MN;Rhead S;Schwarzbold AV;Singh N;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Tarrant R;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;Watson MEE;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1016/s1473-3099(20)30773-8
发表时间：
2021-03
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Hodgson SH;Mansatta K;Mallett G;Harris V;Emary KRW;Pollard AJ
通讯作者：
Pollard AJ
DOI：
10.1159/000509143
发表时间：
2020-07-01
影响因子：
1.3
作者：
Haehner, Antje;Draf, Julia;Hummel, Thomas
通讯作者：
Hummel, Thomas
影响因子：
14.3
作者：
Deb, K;Pratap, A;Meyarivan, T
通讯作者：
Meyarivan, T